- Home
- AIRS vs AMRN Comparison
AIRS vs AMRN Comparison
Compare AIRS & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIRS | AMRN |
|---|---|---|
| Founded | 2012 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.3M | 339.8M |
| IPO Year | 2021 | 1993 |
Fundamental Metrics
Financial Performance| Metric | AIRS | AMRN |
|---|---|---|
| Price | $2.10 | $14.13 |
| Analyst Decision | Hold | Strong Sell |
| Analyst Count | 2 | 1 |
| Target Price | $3.75 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 633.6K | 87.4K |
| Earning Date | 11-07-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $157,554,000.00 | ★ $226,733,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.55 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.53 | $7.08 |
| 52 Week High | $12.00 | $20.90 |
Technical Indicators
Market Signals| Indicator | AIRS | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 23.96 | 41.21 |
| Support Level | $2.07 | $13.50 |
| Resistance Level | $2.36 | $14.30 |
| Average True Range (ATR) | 0.25 | 0.75 |
| MACD | 0.12 | -0.00 |
| Stochastic Oscillator | 4.55 | 25.43 |
Price Performance
Historical ComparisonAbout AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. Elite Body Sculpture, provides custom body contouring using the proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure. The company has one operating and reportable segment, direct medical procedure services.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.